Publications by authors named "Jacobi B Hines"
Article Synopsis
- - The study investigates whether pathologic complete response (pCR) and major pathologic response (MPR) can reliably predict event-free survival (EFS) and overall survival (OS) in neoadjuvant trials for non-small cell lung cancer (NSCLC).
- - A total of seven clinical trials involving 2385 patients were analyzed, demonstrating a strong correlation between pCR/MPR and 2-year EFS, but weaker associations with OS.
- - The conclusion suggests that while pCR and MPR are good indicators of EFS, their predictive value for OS is less clear; further research is needed for more accurate data and understanding of patient outcomes.
Article Synopsis
- Numerous recent clinical trials have examined the use of neoadjuvant immune checkpoint inhibitors (ICIs) over the past five years, highlighting the need for clear trial endpoints.
- Complete pathologic response is a useful indicator for some cancers like breast and bladder cancer, but its relevance in non-small-cell lung cancer (NSCLC) is still being debated.
- The review discusses different types of endpoints—medical (survival and drug effectiveness) and surgical (surgery-related factors)—as well as exploratory endpoints like circulating tumor DNA clearance to enhance ongoing clinical research.
Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents.
View Article and Find Full Text PDFPurpose Of Review: New therapies are needed to potentiate the effects of current immunotherapies and overcome resistance. The stimulator of interferon genes genes (STING) pathway is an innate immune activating cascade that may enhance current cancer immunotherapies.
Recent Findings: Preclinical data has shown that the addition of a STING agonist enhances the effect of current treatments such as immune checkpoint inhibitor antibodies and radiation therapy.